Study
of Interferon Beta-1a IM (Avonex) on FOXP3 Expression in Multiple
Sclerosis Subjects
|
IRB#
2164
|
Principal
Investigator: Dennis Bourdette, M.D.
|
The Multiple Sclerosis
(MS) Center of Oregon at Oregon Health & Science University is
currently recruiting study subjects to participate in a research trial
that will study the effect of interferon beta-1a IM (Avonex) on blood
levels of substances that are associated with MS.
You may be eligible to participate in this study if you meet all
of the following criteria:
- At least 18 years old
- Have a diagnosis of relapsing remitting MS
• Have not used a
disease
modifying therapy in the last three months
• Have not had an MS
relapse in the last three months
• Do not have a
serious
health condition other than MS (like heart disease, uncontrolled
diabetes mellitus, liver disease or severe psychiatric disorders)
This study requires 5 visits to OHSU over a 12-month period. You will
receive 30 for each completed visit. The research study will pay for
all costs associated with the participation in this study. You will be
responsible for any expenses that have to do with other aspects of your
participation, such as childcare or transportation.
If you would like further information about this study, please call the
MS Center of Oregon Research Line at (503) 494-7241.
|
Multiple
Sclerosis (MS) Genetic Susceptibility Research Study
|
IRB#
1494
|
Principal
Investigator: Dennis Bourdette, M.D.
|
The OHSU MS Center of
Oregon in conjunction with the University of California at San
Francisco is currently seeking individuals to participate in a research
study. The purpose of the study is to understand the inheritance
of MS.
You may qualify if you are:
• Over 13 years of
age
• Have MS or a family
member has MS
• Willing to receive
a
one-time blood draw
You will not be compensated for participating in this study. All
study related activities will be of no cost to you.
If you or someone you know is interested in participating, please
contact the MS Center of Oregon at (503) 494-7241 for more information.
|
Study
of Anti-Oxidant in Multiple Sclerosis
|
IRB#
1305
|
Principal Investigator:
Vijayshree Yadav, M.D.
|
The Multiple Sclerosis
(MS) Center of Oregon at Oregon Health & Science University is
looking for people with a confirmed diagnosis of MS to participate in a
research study that will require several blood draws and saliva
collection. The purpose of the study is to determine how the oral
antioxidant, lipoic acid (LA) is absorbed by the body of patients with
a diagnosis of MS.
If you are between 18 and 80 years of age, and have a confirmed
diagnosis of MS, you may be eligible to participate in this study.
You will not be eligible to participate in this study if you are
pregnant or breast feeding, have experienced a relapse in last 30 days,
have taken LA in last 2 weeks, or have a serious health condition other
than MS (e.g. anemia, uncontrolled diabetes, cancer, liver disease,
lung disease, congestive heart failure)
This study requires two visits to OHSU. The research study will pay for
all costs associated with the participation in this study. You will be
eligible to receive $50 as a token compensation at the completion of
the study. You will be responsible for any expenses that have to do
with other aspects of your participation, such as childcare or
transportation.
If you meet the eligibility requirements described above and are
interested in participating in this study, please call Dr. Vijayshree
Yadav at (503) 494-7241.
|
Fish
oil as an adjunct therapy for depression in multiple sclerosis and
Parkinson’s disease: A Randomized, Placebo-controlled Pilot Study.
|
IRB# 179
|
Principal Investigator:
Lynne Shinto, ND
|
The MS Center of Oregon at
Oregon Health & Science University is looking for people with a
confirmed diagnosis of relapsing remitting MS who are suffering from
depression. The purpose of the study is to determine if taking omega-3
fatty acids helps with symptoms of depression in people with MS. In
addition we will determine if omega-3 fatty acids decrease blood levels
of substances that are associated with MS and depression
You may be eligible to participate in the study if you meet the all of
the following criteria:
• 18-85
years old
• Have a
diagnosis of relapsing remitting MS
• If
using disease modifying medications, participant must be on a stable
dose at least 6 months prior
to enrollment
• On a
stable dose of anti-depressant medication
• Have
not had an MS relapse or received corticosteroid treatment 1 month
prior to enrollment
• Have
not eaten more than one 6 oz serving of fish per week 1 month prior to
enrollment
• Have
not taken fish oil or omega-3 fatty acid supplementation 1 month prior
to enrollment
• Not
pregnant
• Have no
other significant health conditions (like coronary heart disease,
uncontrolled diabetes mellitus, liver disease, severe psychiatric
disorders)
• Not
participating in any other studies
This is a three-month pilot study in which 60 participants will be
randomly assigned to receive either fish oil capsules (which have high
amounts of omega-3 fatty acids) or placebo oil capsules.
The study requires 3 visits to OHSU. The research study will pay for
all costs associated with the participation in this study. You will be
responsible for any expenses that have to do with other aspects of your
participation such as childcare and transportation.
If you meet the eligibility requirements described above and are
interested in participating in this study please call Lilia Alvarez at
(503) 494-3549.
|
Ginseng
for Multiple Sclerosis Related Fatigue
|
IRB# 1357
|
Principal Investigator:
Ruth Whitam, M.D.
|
The MS Center of Oregon is
currently recruiting study subjects to enroll in a placebo controlled
cross-over design trial that will study the effect of an American
Ginseng extract on multiple sclerosis related fatigue.
To enroll in the study, subjects must:
• be between the ages
of 18 and 65 years,
• carry a diagnosis
of multiple sclerosis and
• have problems with
fatigue for greater than two months.
Participation in the study requires that subjects undergo clinical
assessments at OHSU on seven separate occasions over a 17-week period.
There will be two 6-week treatment periods, separated by a 2-week
washout period. All subjects take ginseng for one treatment period and
placebo for one treatment period. Those participating in the study will
be asked to wear activity monitors at the waist and wrist for several
weeks over the course of the study. Clinical assessments will be done
at the beginning and end of each treatment period and will involve
physical exams, questionnaires, blood draws and collection of saliva
samples.
There will be no financial costs to subjects who choose to participate
in this study.
If you would like further
information about this study or to refer a subject, please contact:
The MS Center of Oregon Research Line at (503) 494-7241
This study will take place in association with the MS Center of Oregon
at Oregon Health & Science University in Portland, Oregon.
|
